Journal profile · Medicine-Medicine (all)
Ophthalmology. Glaucoma
ISSN 2589-4196 · Elsevier
Ophthalmology. Glaucoma: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 3.3 (journal website); subscription journal; APC about USD 3,300; median 105 days to acceptance (106 articles, last 24 months); 132 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Ophthalmology. Glaucoma is published by Elsevier and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Glaucoma and retinal disorders, Retinal Diseases and Treatments and Corneal surgery and disorders, together about 54.3% of its articles. Its main subfields are Ophthalmology and Radiology, Nuclear Medicine and Imaging. (generated from OpenAlex topic counts and CAS ranking data)
Ophthalmology Glaucoma, a journal collaboration between the American Academy of Ophthalmology and the American Glaucoma Society, provides a stimulating forum for discussion of clinical and scientific issues of greatest concern to clinicians who care for glaucoma patients. Each issue presents original articles on new approaches to diagnosis, innovations in pharmacological therapy and surgical technique, and basic science advances that impact clinical practice. Ophthalmology Glaucoma is the official journal of the American Glaucoma Society.Disclaimer Notice: Statements and opinions expressed in Ophthalmology Glaucoma are those of the author(s) and are not necessarily those of the Academy or publisher, or indicative of Academy views, policy or editorial concurrence. The Editor(s), the Academy, and the Publisher assume no responsibility for any injury and/or damage to persons or property as a matter of product liability, negligence, or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein including those in a language other than English. No suggested test or procedure should be carried out unless, in the reader's judgment, its risk is justified and the patient has received information sufficient to give a fully informed consent. Because of the rapid advances in the medical sciences, medical practitioners should obtain independent verification of diagnoses and drug dosages. Discussions, views, and recommendations as to medical procedures, choice of drugs, and drug dosages are the responsibility of the authors. Consumers should consult with their own doctors about their individual health status before making any health decisions. The Academy does not endorse companies, drugs or other products.
From the journal's Aims & Scope
Research area (LetPub): Medicine-Medicine (all)
Editor-in-chief Henry JampelPublisher website
Editorial board by country: none in mainland China; most named United States 8, Singapore 4, Canada 2, United Kingdom 1 (15 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Glaucoma and retinal disordersMedicine31.7%
- Retinal Diseases and TreatmentsMedicine11.9%
- Corneal surgery and disordersMedicine10.7%
- Ophthalmology and Visual Impairment StudiesMedicine8.9%
- Retinal and Macular SurgeryMedicine8.3%
- Intraocular Surgery and LensesMedicine6%
- Retinal Imaging and AnalysisMedicine2.9%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance2.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Ophthalmology | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Ophthalmology | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 3.3Publisher website ·
- CiteScore 2026-06
- 5.7LetPub ·
- CiteScore (publisher)
- 5.7Publisher website ·
- SJR 2026-06
- 1.28LetPub ·
- SNIP 2026-06
- 1.46LetPub ·
- h-index
- 40OpenAlex ·
- i10-index
- 243OpenAlex ·
- 2-year mean citedness
- 1.92OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 965 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 104 | 39 | 23 |
| 2025 | 132 | 50 | 233 |
| 2024 | 103 | 39 | 395 |
| 2023 | 99 | 30 | 651 |
| 2022 | 109 | 42 | 942 |
| 2021 | 127 | 34 | 1,407 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
105 daysMedian, submission to acceptance · P25–P75 61 days – 153 days
- Acceptance to online
- median 8 days (106 articles)
- Submission to online
- median 115 days
- Sample
- 106 articles with submission and acceptance dates (267 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Submission to first decision
- 9 daysPublisher website ·
- First decision after review
- 44 daysPublisher website ·
- Submission to acceptance
- 81 daysPublisher website ·
- Acceptance to publication
- 8 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,300 / EUR 3,090 / GBP 2,640 / JPY 409,300 | — | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare5 items from the author guidelines
- Abstract
- ≤ 350 words
- Keywords
- ≥ 3
- Reference style
- AMA
- First submission
- Free format: the journal's layout is not required
- Cover letter
- Required
Article types accepted10, with length limits
- ags meeting paperAGS Meeting Paper – A manuscript based on material that has or will be presented at an American Glaucoma Society (AGS) Annual Meeting.Length not stated
- correspondenceCorrespondence allows concise commentary about an article published in the journal within 8 months of its online posting. The text should raise a question for c…main text ≤ 700 words · references ≤ 5
- editorialEditorials are usually solicited by the Editor-in-Chief. While unsolicited submissions are welcome, they are rarely considered. Editorials may address clinical …main text ≤ 1,700 words
- manuscriptsManuscripts – A standard submission; a manuscript that does not fall into any of the following categories:Length not stated
- pictures & perspectivesPictures & Perspectives – Photographs, photomicrographs, radiologic or other imaging studies, or procedural illustrations that depict novel features of clinical…Length not stated
- report (invited)Report (Invited) – Typically by invitation from the Editorial Board.Length not stated
- reviewIt is the corresponding author’s responsibility to check periodically the status of his/her manuscript. An email with a decision will be sent with instructions …Length not stated
- systematic reviewSystematic reviews seek to collect, synthesize, and critically assess all evidence that fits pre-specified criteria to answer a clinical question pertaining to …Length not stated
- systematic review or meta-analysisSystematic Review or Meta-analysis – Please see specific criteria for submission in the Systematic Review/ Meta-analysis in this Guide.Length not stated
- translational science reviewsTranslational Science Reviews – Typically by invitation from the Editorial Board.Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Plagiarism, Preprints, Trial registration / reporting guidelines
- AI use Declaration of generative AI in scientific writing
Where authors use generative artificial intelligence (AI) and AI-assisted technologies in the writing process, authors should only use these technologies to improve readability and language. Applying the technology should be done with human oversight and control, and authors should carefully review and edit the result, as AI can generate authoritative-sounding output that can be incorrect, incompl…
Source ↗Publisher website ·- Authorship Authorship
The journal adheres to the Uniform Requirements set by the International Committee of Medical Journal Editors (https://www.icmje.org/) for authorship. Each author must meet criteria for Authorship. The ICMJE recommends that authorship be based on the following 4 criteria:Substantial contributions to conception or design of the work; or the acquisition, analysis, or interpretation of data for the w…
Source ↗Publisher website ·- Conflicts of interest Disclosure instructions
Authors must disclose the use of generative AI and AI-assisted technologies in the writing process by adding a statement at the end of their manuscript in the core manuscript file, before the References list. The statement should be placed in a new section entitled ‘Declaration of Generative AI and AI-assisted technologies in the writing process’. Statement: During the preparation of this work the…
Source ↗Publisher website ·- Publication ethics Publication Ethics
Before completing the submission, authors must confirm that their submission conforms with the Elsevier Guidelines for Ethics in Publishing, see https://www.elsevier.com/publishingethics and https://www.elsevier.com/ethicalguidelines.
Source ↗Publisher website ·- License & copyright Copyright
Upon acceptance of an article, authors will be asked to complete a ‘Journal Publishing Agreement’ (for more information on this and copyright, see https://www.elsevier.com/copyright). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a ‘Journal Publishing Agreement’ form or a link to the online version of this agreement.Subscribers may reproduce …
Source ↗Publisher website ·- Open access Open Access
Embargo period of 12 months Model summary
This journal offers authors a choice in publishing their research:Open access• Articles are freely available to both subscribers and the wider public with permitted reuse• An open access publication fee is payable by authors or on their behalf (e.g., by their research funder or institution)Subscription• Articles are made available to subscribers as well as developing countries and patient groups t…
Source ↗Publisher website ·- Peer review Peer Review
This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor-in-Chief is responsible for the final decision regarding acceptance or rejection of articles. Th…
Source ↗Publisher website ·- Plagiarism Prior and Repetitive Publication; Plagiarism
The journal will not consider manuscripts that have appeared in other journals, in part or in whole, except in special circumstances approved by the Editor-in-Chief. Likewise, updates of previously published studies that add minimal new information to an existing publication will not be considered. Overlap between patient groups described in serial manuscripts must be acknowledged, and references …
Source ↗Publisher website ·- Preprints Preprint Server
For work submitted to a preprint server, it is the corresponding author's responsibility to promptly update the preprint server entry to indicate when a paper has been accepted and is currently in press; the author must add proper citation of the online version to the preprint server entry to point users to the peer-reviewed, accepted version of the article.
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trials and Clinical Trial Registration
A clinical trial is defined as any study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. With regards to the reporting of clinical trials, Ophthalmology Glaucoma's policies are similar to the policies of The New England Journal of Medicine (NEJM), and The Journal of the American Medical Associ…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- ISSN
- 2589-4196
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Ophthalmology. Glaucoma
What CAS zone is Ophthalmology. Glaucoma in?
In the 2025 upgraded edition of the CAS Journal Ranking, Ophthalmology. Glaucoma is in Zone 3 of Medicine, and in Zone 2 of the minor category Ophthalmology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Ophthalmology. Glaucoma?
The journal's website gives an impact factor of 3.3; this is the journal's own figure, as LetPub lists none for it; CiteScore 5.7, h-index 40.
How long does peer review take at Ophthalmology. Glaucoma?
Based on the dates recorded on 106 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 105 days (interquartile range 61–153 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Ophthalmology. Glaucoma?
According to the journal's author guidelines: Abstract: ≤ 350 words; Keywords: ≥ 3; Reference style: AMA; First submission: Free format: the journal's layout is not required; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Ophthalmology. Glaucoma based?
Of the 15 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (8), Singapore (4) and Canada (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Ophthalmology. Glaucoma?
According to LetPub and DOAJ records, Ophthalmology. Glaucoma is indexed in Scopus.
Is Ophthalmology. Glaucoma open access, and what is the APC?
Ophthalmology. Glaucoma is a subscription journal. APC about USD 3,300.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .